Sera Prognostics Inc
NASDAQ:SERA
Sera Prognostics Inc
NASDAQ:SERA
Price:
10.7 USD
2.59%
Market Closed
Updated:
May 2, 2024
Section:
Relative Value
The Relative Value of one
SERA
stock under the Base Case scenario is
4.41
USD.
Compared to the current market price of 10.7 USD,
Sera Prognostics Inc
is
Overvalued by 59%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
SERA
Relative Value
Base Case
4.41
USD
Overvaluation 59%
Valuation Multiples
Multiples Across Competitors
SERA Competitors Multiples
Sera Prognostics Inc Competitors
Sera Prognostics Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Sera Prognostics Inc
NASDAQ:SERA
|
339.2m USD | 1 108.6 | -9.4 | -7.2 | -7.1 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
281.3B USD | 5.2 | 58.4 | 12.7 | 19.4 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
148.1B USD | 5.3 | 22 | 16.4 | 24.5 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
103.8B USD | 10.5 | 28.7 | 23 | 24 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
101.7B USD | 7.8 | 25.7 | 17.2 | 18.9 | |
| AU |
|
CSL Ltd
ASX:CSL
|
133B AUD | 6.1 | 35.1 | 21.3 | 26.4 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
81.1B USD | 3 | 167.6 | 6.7 | 8.8 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
45.8B USD | 6.7 | -9.7 | -10.4 | -8.9 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
31.3B USD | 3.2 | 26.8 | 13.8 | 17.2 | |
| KR |
|
Celltrion Inc
KRX:068270
|
38.9T KRW | 17.9 | 72.5 | 44.4 | 61.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
